Colombia Gianfranco Biliotti, recently appointed General Manager for Alexion Colombia, shares his insights on the particularities of operating in the ultra-rare disease segment, while highlighting the importance of managerial flexibility, the company’s unmatched patient-centricity and close ties with doctors, the role of education in improving patients’ lives and his strategic priorities…
Taiwan Joanna Yao, general manager of Taiwan & Hong Kong at Baxter, documents the company’s commitment to bring the most innovative renal diseases solutions and expertise to Taiwanese patients and physicians and the strategic role played by the affiliate in nurturing an innovation-centered relationship that originates from Taiwan’s world-class healthcare system and…
Taiwan Dr. Tzu-Ling (Karen) Tseng, CEO of Bio Preventive Medicine Corporation in Taiwan, discusses the innovative technology of its patented biomarkers, the success of DNlite and company’s strategy to grow through partnerships with global pharmaceutical companies. What was your vision when you founded Bio Preventive Medicine Corporation (BPM) in 2014? Can…
Mexico Joel Osorio, CEO & Founder Alejandro De La Parra, Co-Founder & Chief Operating Officer Alexa Jeppi, Co-Founder, RegenerAge Beauty & Health Ira Pastor, Board Member The CEO of RegenerAge, Dr. Joel Osorio, explains the transformative power of Bioquantine—a novel biological complex used in regenerative…
Greece A strong proponent of the value of orphan drugs, Shire Greece’s Managing Director, Christos Dakas, shares his insights on the recent merger with Baxalta, the necessity of exempting orphan and haemophilia drugs from clawbacks to circumvent market challenges for critical treatments, as well as his vision for the bright future…
Philippines Cheryl Maley, General Manager of Novartis Philippines, discusses the company’s operations in the country, their growing portfolio of products as well as their impressive focus on research and development in the Philippines. She also discusses some of her key objectives and goals for her first country leadership role. As an…
Ireland James Lennertz, Group VP and GM EUMEA for BioMarin, discusses the key highlights of the past few years for BioMarin, their unique positioning as a company offering innovative therapies for ultra-rare diseases, the main challenge he sees for BioMarin’s international operations, and his priorities for the next few years. James,…
Switzerland Specializing in ultra-rare diseases, Alexion targets patient populations of less than 20 patients per million. Christophe Bourdon discusses Alexion’s progress towards developing access for patients across the EMEA region. Since day one, Alexion’s mission has been to focus solely on discovering treatments for patients affected by these incredibly rare…
Mexico Leonardo Torres, general manager Mexico, Central America & Caribbean of Shire, provides insights into the rapidly progressing integration of Baxalta in Mexico, while he also highlights his key priorities to further accelerate the growth and consolidate the strategic positioning of Shire, a company that now proudly stands out as the…
Mexico Mario Sturion, the recently appointed general manager of Janssen Mexico, assesses the specific challenges and opportunities of the Mexican health system and explains how a customized market access approach has been critical to Janssen’s success in a country noteworthy for the complexity of its public health system. You took over…
Switzerland Dr. Andrea Michael Meyer, general manager of Sanofi Genzyme Switzerland, reveals how the Swiss business has been experiencing year-on-year double-digit growth; how rare diseases was the foundation of Sanofi Genzyme´s business and remains a key part of their DNA; and how a focus on patient centricity remains at the core…
Singapore Recently established in Singapore, Holmusk is a global digital health platform that truly believes in early detection and early intervention. Founder and CEO Nawal Roy describes the underlying motivations behind the company’s founding, the value of positively influencing patient behavior—particularly in tackling chronic diseases—, and how their technology benefits not…
See our Cookie Privacy Policy Here